{
    "name": "lifitegrast ophthalmic",
    "comment": "Rx",
    "other_names": [
        "Xiidra"
    ],
    "classes": [
        "LFA-1 Agonists"
    ],
    "source": "https://reference.medscape.com/drug/xiidra-lifitegrast-ophthalmic-1000032",
    "pregnancy": {
        "common": [
            "There are no available data regarding use in pregnant women to inform any drug-associated risks"
        ],
        "specific": [
            {
                "type": "Animal data (IV administration)",
                "description": [
                    "Lifitegrast administered daily by IV injection to rats, from premating through gestation day 17, caused an increase in mean preimplantation loss and an increased incidence of several minor skeletal anomalies at 30 mg/kg/day, representing 5,400-fold the human plasma exposure at the recommended human ophthalmic dose (RHOD)",
                    "In rabbits, an increased incidence of omphalocele was observed at the lowest dose tested, 3 mg/kg/day (400-fold the human plasma exposure at the RHOD, based on AUC), when administered by IV injection daily from gestation days 7 through 19"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of lifitegrast in human milk; systemic exposure to lifitegrast from ocular administration is low"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug or excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Patients should not touch the tip of the single-use container to their eye or to any surface, in order to avoid eye injury or contamination of solution",
                "Advise patients that contact lenses should be removed prior to administration; lenses can be reinserted 15 minutes after administration",
                "Advise patients that the solution from one single-use container is to be used immediately after opening; can be used to dose both eyes",
                "Single-use container, including any remaining contents, should be discarded immediately after administration"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Instillation site irritation",
            "percent": "5-25"
        },
        {
            "name": "Dysgeusia",
            "percent": "5-25"
        },
        {
            "name": "Reduced visual acuity",
            "percent": "5-25"
        },
        {
            "name": "Blurred vision",
            "percent": "1-5"
        },
        {
            "name": "Conjunctival hyperemia",
            "percent": "1-5"
        },
        {
            "name": "Eye irritation",
            "percent": "1-5"
        },
        {
            "name": "Headache",
            "percent": "1-5"
        },
        {
            "name": "Increased lacrimation",
            "percent": "1-5"
        },
        {
            "name": "Eye discharge",
            "percent": "1-5"
        },
        {
            "name": "Eye discomfort",
            "percent": "1-5"
        },
        {
            "name": "Eye pruritus",
            "percent": "1-5"
        },
        {
            "name": "Sinusitis",
            "percent": "1-5"
        },
        {
            "name": "Serious hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including anaphylactic reaction",
            "percent": null
        },
        {
            "name": "bronchospasm",
            "percent": null
        },
        {
            "name": "respiratory distress",
            "percent": null
        },
        {
            "name": "pharyngeal edema",
            "percent": null
        },
        {
            "name": "swollen tongue",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "allergic conjunctivitis",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "and allergic dermatitis",
            "percent": null
        },
        {
            "name": "eye swelling and rash also reported",
            "percent": null
        }
    ]
}